5HZ1 Stock Chart & Stats
€5.70
-€0.08(-2.33%)
At close: 4:00 PM EST
€5.70
-€0.08(-2.33%)
Day’s Range― - ―
52-Week Range€3.22 - €5.90
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.66B
Enterprise Value€33.48K
Total Cash (Recent Filing)€2.15B
Total Debt (Recent Filing)€2.35B
Price to Earnings (P/E)710.1
Beta0.75
Next Earnings
Oct 22, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding123,124,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.87Price Target Upside2.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.08
Revenue Forecast (FY)€1.00B
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong Equity BaseA conservative capital structure gives Tigermed financial flexibility to sustain operations, fund development, and absorb business cycles without heavy debt servicing pressure. Its substantial equity base also supports resilience and reduces dependence on external financing as market conditions change.
Strong, Cash-backed Free Cash FlowPositive operating and free cash flow provide internally generated funding for investment, client delivery, and shareholder returns. Strong free-cash-flow growth and conversion relative to earnings indicate that reported profits are substantially supported by cash, strengthening financial durability.
Resumed Revenue GrowthThe return to revenue growth suggests renewed demand for Tigermed’s outsourced clinical research and development-support services after the prior-year contraction. If sustained, expanding revenue can improve operating scale, deepen client activity, and support recovery in earnings over the coming periods.
Bears Say
Material Margin CompressionThe substantial decline in gross and net margins indicates that revenue is currently producing less profit than in earlier years. Persistent margin pressure would weaken operating leverage, reduce the benefit of future sales growth, and make earnings recovery dependent on cost control or improved service mix.
Sharp Deterioration In ProfitabilityThe steep fall in net income and low return on equity show that the company is using its substantial equity base less effectively than before. This weakens internal capital generation and signals that improved revenue alone may not restore prior earnings power without better profitability.
Volatile Operating Cash-flow CoverageAlthough free cash flow remains positive, inconsistent operating cash-flow coverage relative to reported profitability points to working-capital or timing volatility. Such variability can make cash planning less predictable and may constrain the reliability of internally funded investment during weaker operating periods.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
5HZ1 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was €3.22 and its highest was €5.90 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is €5.66B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Oct 22, 2026 which is in 24 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Aug 28, 2026. The company reported -€0.07 earnings per share for the quarter, missing the consensus estimate of €0.028 by -€0.098.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H does not currently pay dividends.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.04.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of -€0.07 in its last earnings report, missing expectations of €0.028. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in DE:5HZ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.87 (2.94% Upside)
€5.87 (2.94% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.47%
12-Months-Change
Fundamentals
Return on Equity
0.31%
Trailing 12-Months
Asset Growth
6.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
5HZ1 Stock 12 Month Forecast
Average Price Target
€5.87
▲(2.94% Upside)
Technical Analysis
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
ADICON Holdings Limited
―
WuXi XDC Cayman, Inc.
―